Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 12/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5708342 | 1.00 | HTT (0.56) | HTTLMNASMN1; SMN2CASP1ALDH1A1 | |
| SCHEMBL5019087 | 0.91 | LMNA (0.61) | HTTLMNASMN1; SMN2ALDH1A1SYK | |
| SCHEMBL223222 | 0.90 | LMNA (0.54) | HTTLMNASMN1; SMN2CASP1ALDH1A1 | |
| SCHEMBL20530482 | 0.88 | ALDH1A1 (0.54) | HTTLMNASMN1; SMN2ALDH1A1SYK | |
| SCHEMBL19615746 | 0.88 | LMNA (0.52) | HTTLMNASMN1; SMN2CASP1ALDH1A1 | |
| SCHEMBL19615744 | 0.88 | LMNA (0.52) | HTTLMNASMN1; SMN2CASP1ALDH1A1 | |
| SCHEMBL30642172 | 0.87 | LMNA (0.51) | HTTLMNASMN1; SMN2CASP1ALDH1A1 | |
| SCHEMBL334682 | 0.86 | LMNA (0.56) | HTTLMNASMN1; SMN2ALDH1A1SYK | |
| SCHEMBL1569295 | 0.86 | LMNA (0.56) | HTTLMNASMN1; SMN2ALDH1A1SYK | |
| SCHEMBL12067897 | 0.86 | LMNA (0.56) | HTTLMNASMN1; SMN2ALDH1A1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10304893-A | — | — | None | — | — | JP | disclosed |
| WO-2023220715-A1 | OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20180134695-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2018-05-17 | — | — | US | disclosed |
| US-9896444-B2 | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| EP-2861576-B1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2018-01-10 | — | — | EP | disclosed |
| US-20160200705-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2016-07-14 | — | — | US | disclosed |
| US-9340537-B2 | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVATIS AG (CH) | 2016-05-17 | — | — | US | disclosed |
| US-20150126485-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| EP-2861576-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | Novartis AG (CH) | 2015-04-22 | — | — | EP | disclosed |
| WO-2013171642-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2013-11-21 | — | — | WO | disclosed |
| US-8088925-B2 | low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | disclosed |
| EP-1888567-B1 | HETEROARYL-CARBOXYLIC ACID (SULFAMOYL ALKYL) AMIDE - DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI AVENTIS (FR) | 2009-12-16 | — | — | EP | disclosed |
| US-20080167346-A1 | low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents | SANOFI-AVENTIS (FR) | 2008-07-10 | — | — | US | disclosed |
| EP-1888567-A1 | HETEROARYL-CARBOXYLIC ACID (SULFAMOYL ALKYL) AMIDE - DERIVATIVES AS FACTOR XA INHIBITORS | Sanofi-Aventis (FR) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006122661-A1 | HETEROARYL-CARBOXYLIC ACID (SULFAMOYL ALKYL) AMIDE - DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS (DE) | 2006-11-23 | — | — | WO | disclosed |
| EP-1008590-B1 | Process for preparing optically active oxazolidinone derivatives | TAKASAGO PERFUMERY CO LTD (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-6403804-B1 | ALLOWING HYDRAZINE TO REACT ON OPTICALLY ACTIVE ACID ESTER HAVING HYDROXYL GROUP AT 3-POSITION TO GIVE OPTICALLY ACTIVE HYDRAZIDE HAVING HYDROXYL GROUP AT 3-POSITION, SUBJECTING OPTICALLY ACTIVE HYDRAZIDE TO CURTIUS REARRANGEMENT | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-06-11 | — | — | US | disclosed |
| EP-1008590-A1 | Process for preparing optically active oxazolidinone derivative | Takasago International Corporation (JP) | 2000-06-14 | — | — | EP | disclosed |
| JP-H10304893-A | PRODUCTION OF OPTICALLY ACTIVE COMPOUND | DAI ICHI SEIYAKU CO LTD | 1998-11-17 | — | — | JP | disclosed |
| US-4965250-A | TETRAPEPTIDE; IMMUNE SYSTEM ACTIVATION | ADIR ET CIE (FR) | 1990-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200705-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ABL1, ABL2, BCR | HTT 3819/4885LMNA 4457/4885SMN1; SMN2 3874/4885 |
| US-20080167346-A1 | low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents | TFPI, SERPINC1, PLAT | HTT 4816/4885LMNA 1704/4885SMN1; SMN2 3949/4885 |
| US-20150126485-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ABL1, ABL2, BCR | HTT 4042/4885LMNA 4722/4885SMN1; SMN2 3946/4885 |
| US-20180134695-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ABL1, ABL2, BCR | HTT 3546/4885LMNA 4592/4885SMN1; SMN2 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.